Compile Data Set for Download or QSAR
Report error Found 68 Enz. Inhib. hit(s) with all data for entry = 9913
TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498860((R)—N-(3-(3-Chlorophenyl)isoxazol-5-yl)-2-(1-...)
Affinity DataIC50: 5.5nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498874(US11014912, Example 50)
Affinity DataIC50: 5.5nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498875(US11014912, Example 51)
Affinity DataIC50: 5.5nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498879(US11014912, Example 55)
Affinity DataIC50: 5.5nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498878(US11014912, Example 54)
Affinity DataIC50: 5.5nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498890(US11014912, Example 68)
Affinity DataIC50: 55nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498862(US11014912, Example 38)
Affinity DataIC50: 55nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498863((S)-3-(2-(3-(4-Methoxy-3-(1H-pyrazol-5-yl)phenyl)a...)
Affinity DataIC50: 55nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498864((S)-3-(2-(3-(4-Methoxy-3-(1-methyl-1H-pyrazol-5-yl...)
Affinity DataIC50: 55nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498866(US11014912, Example 42)
Affinity DataIC50: 55nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498867(US11014912, Example 43)
Affinity DataIC50: 55nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498846(2-(1-Cyanopyrrolidin-3- ylidene)-N-(4- phenoxyphen...)
Affinity DataIC50: 55nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498877(US11014912, Example 53)
Affinity DataIC50: 55nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498889(US11014912, Example 67)
Affinity DataIC50: 55nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498883(US11014912, Example 59)
Affinity DataIC50: 55nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498884(US11014912, Example 60)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498858((S)—N-(3-(4-Chlorophenyl)isoxazol-5-yl)-2-(1-...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498825(US11014912, Example 1)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498859((R)—N-(3-(4-Chlorophenyl)isoxazol-5-yl)-2-(1-...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498861((S)—N-(3-(3-Methoxyphenyl)isoxazol-5-yl)-2-(1...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498887(US11014912, Example 65)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498892(US11014912, Example 64)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498865(US11014912, Example 41)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498891(US11014912, Example 62)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498880(US11014912, Example 56)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498869(US11014912, Example 45)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498871(US11014912, Example 47)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498872(US11014912, Example 48)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498873(US11014912, Example 49)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498882(US11014912, Example 58)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498881(US11014912, Example 57)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498876(US11014912, Example 52)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498856(N-(Benzo[d]thiazol-2-yl)-2-(1- cyanopyrrolidin-3-y...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498826(N-(3-Chlorophenyl)-2-(1- cyanopyrrolidin-3-yl)acet...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498827(2-(1-Cyanopyrrolidin-3-yl)-N-(6- methoxybenzo[d]th...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498829(N-(6-Chlorobenzo[d]thiazol-2- yl)-2-(1-cyanopyrrol...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498830(2-(1-Cyanopyrrolidin-3-yl)-N-(3- phenylisoxazol-5-...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498831(2-(1-Cyanopyrrolidin-3-yl)-N-(5- phenylpyrrolidin-...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498832(N-(5-Chlorobenzo[d]oxazol-2- yl)-2-(1-cyanopyrroli...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498833(2-(1-Cyanopyrrolidin-3-yl)-N- (3,4-dichlorophenyl)...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498834(2-(1- Cyanopyrrolidin-3- yl)-N-(5- phenylthiazol-2...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498836(3-(2-Oxo-2-(3- phenoxyazetidin-1- yl)ethyl)pyrroli...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498837(3-(2-(3-(3- Methoxyphenyl) azetidin-1-yl)-2- oxoet...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498838(2-(1- Cyanopyrrolidin-3- yl)-N-(3,4- dichloropheny...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498841(US11014912, Example 17)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498842(3-(2-Oxo-2-(3-phenylazetidin-1-yl)ethylidene)pyrro...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498843(N-(3-Chloro-4-methylphenyl)- 2-(1-cyanopyrrolidin-...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498850(2-(1-Cyanopyrrolidin-3- ylidene)-N-methyl-N-(3- (p...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498857(2-(1-Cyanopyrrolidin-3- ylidene)-N-(3,4- dichlorob...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM498854(2-(1-Cyanopyrrolidin-3- ylidene)-N-methyl-N-((5- p...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 68 total ) | Next | Last >>
Jump to: